CC
ARQT icon

Corton Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Corton Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$191K Sell
10,130
-6,813
-40% -$107K 0.47% 121
2025
Q2 		$238K Buy
+16,943
New +$238K 0.28% 154
2025
Q1 		– Sell
-15,933
Closed -$222K – 187
2024
Q4 		$222K Buy
+15,933
New +$175K 0.13% 228
2024
Q3 		– Sell
-27,899
Closed -$259K – 487
2024
Q2 		$259K Buy
+27,899
New +$252K 0.14% 240

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Corton Capital's ARQT Position: Q3 2025 in Review

Corton Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 40% in Q3 2025, selling an estimated $107K and leaving 10,130 shares worth $191K. The position accounts for 0.47% of the portfolio, ranked #121.

Corton Capital first reported a position in ARQT in Q2 2024 and has held it in 4 quarters since. The position peaked at $259K in Q2 2024. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Corton Capital held 10,130 shares of Arcutis Biotherapeutics worth $191K as of Q3 2025.
  • Corton Capital sold 6,813 Arcutis Biotherapeutics shares in Q3 2025, an estimated $107K.
  • Arcutis Biotherapeutics made up 0.47% of Corton Capital's portfolio in Q3 2025, its #121 holding.
  • Corton Capital first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • Corton Capital's Arcutis Biotherapeutics position peaked at $259K in Q2 2024.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.